## Glenmark Pharmaceuticals Limited (GLENMARK) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Glenmark Pharmaceuticals Limited (GLENMARK) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) since February 7, 2000.  It operates in the Pharmaceuticals industry and holds a significant position within the Indian pharmaceutical sector, known for its presence in both domestic and international markets.


**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,545.00       |                                                                      |
| Percentage Change (PChange) | 0.27%           | Positive change indicating recent upward price movement.             |
| Pre-Open Activity          | ₹1,530.05       | Opened lower than the previous close, suggesting some initial selling pressure. |
| Week High                    | ₹1,830.95       | Significant high indicating recent volatility.                       |
| Week Low                     | ₹771.00         | Significant low indicating recent volatility.                       |
| VWAP                        | ₹1,546.06       | Volume Weighted Average Price close to the current price.           |
| Sector PE                   | 0               | Data unavailable.                                                   |
| Symbol PE                   | 0               | Data unavailable.                                                   |
| Delivery Percentage         | 50.55%          | Moderate delivery percentage, suggesting a mix of long-term and short-term investors. |
| Market Depth                | Low              | Based on the provided pre-open order book data, market depth appears low.  This suggests limited liquidity and potential for significant price swings. |


**3. Financial Performance:**

The following table summarizes Glenmark's financial performance over the past five quarters.  Note that the data provided includes both audited and unaudited figures.  Further analysis would require access to complete audited statements.

| Quarter Ending      | Revenue (₹ in Lakhs) | Expenses (₹ in Lakhs) | Profit After Tax (₹ in Lakhs) | EPS (₹) |
|----------------------|-----------------------|-----------------------|-----------------------------|---------|
| 30-Sep-2024 (U)     | 2719.17               | 1924.12               | 595.06                      | 21.09    |
| 30-Jun-2024 (U)     | 2385.18               | 1766.87               | 453.73                      | 16.08    |
| 31-Mar-2024 (A)     | 2934.49               | 1786.56               | 4613.69                     | 163.50   |
| 31-Dec-2023 (U)     | 1623.91               | 1674.13               | -20.41                      | -0.72    |
| 30-Sep-2023 (U)     | 2279.63               | 1870.60               | 302.35                      | 10.72    |

**Key Observations:**

* Significant fluctuation in Profit After Tax and EPS across quarters.  The exceptionally high PAT and EPS in Q4 2024 requires further investigation to understand the contributing factors.
* The negative PAT and EPS in Q3 2023 indicate a period of financial weakness.


**4. Corporate Actions and Announcements:**

Glenmark has consistently paid dividends over the past several years, with the most recent dividend of ₹2.50 per share having an ex-date of September 13, 2024.  Recent announcements include several press releases and updates regarding acquisitions and analyst meetings.  These announcements suggest ongoing corporate activity and potential for future growth.


**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|-----------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023     | 46.65                       | 53.35      | 0.00                            | 100.00    |
| 31-Dec-2023     | 46.65                       | 53.35      | 0.00                            | 100.00    |
| 31-Mar-2024     | 46.64                       | 53.36      | 0.00                            | 100.00    |
| 30-Jun-2024     | 46.65                       | 53.35      | 0.00                            | 100.00    |
| 30-Sep-2024     | 46.65                       | 53.35      | 0.00                            | 100.00    |

**Key Observations:**

Shareholding patterns remain relatively stable over the past year, with consistent promoter and public holdings.


**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low prices.  The low market depth further amplifies this risk.  The risk-reward profile is currently skewed towards higher risk due to the volatility and lack of liquidity.


**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Ongoing corporate actions suggesting growth potential.
* Established presence in the pharmaceutical sector.


**8. Disadvantages and Risks:**

* High volatility and low liquidity.
* Inconsistent financial performance across quarters.
* Dependence on the pharmaceutical sector, which is susceptible to regulatory changes and market fluctuations.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Don't Buy.** The high volatility and low market depth make short-term trading risky.  The pre-open activity also suggests potential downward pressure.

* **Medium-term (3 to 12 months): Hold (if you have stock).**  The medium-term outlook depends on the company's ability to maintain consistent financial performance and capitalize on its recent acquisitions.  Further investigation into the Q4 2024 results is crucial.

* **Long-term (1 year and beyond): Hold (if you have stock).**  Glenmark's established position in the pharmaceutical sector and consistent dividend payouts offer some long-term appeal. However, the company needs to demonstrate more consistent financial performance to justify a "Buy" recommendation.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.0**

* Financial Health: 5/10 (Inconsistent performance, requires further investigation of Q4 2024 results)
* Market Performance: 6/10 (Moderate price change, high volatility)
* Volatility and Risk: 4/10 (High volatility, low liquidity)
* Corporate Actions & Governance: 8/10 (Consistent dividends, active corporate actions)
* Shareholding Patterns: 7/10 (Stable shareholding)

**Analysis Score (out of 10): 8.5**

* Completeness and Data Utilization: 9/10 (Most data points were used effectively)
* Accuracy and Clarity: 8/10 (Analysis is clear, but some data points were missing or incomplete)
* Professional Formatting: 9/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Given the high volatility, inconsistent financial performance, and low market depth, a "Don't Buy" recommendation is given for the short term.  For the medium and long term, a "Hold" recommendation is given, contingent upon further analysis of the Q4 2024 financial results and the company's ability to demonstrate consistent growth and profitability.  Investors should closely monitor the company's financial reports and news releases before making any investment decisions.  The significant jump in EPS and PAT in Q4 2024 needs further investigation before a more definitive recommendation can be made.
